Benmelstobart Extends PFS After Chemoradiotherapy in NSCLC
Summary
Researchers evaluate benmelstobart, with or without anlotinib, for use as consolidation therapy after chemoradiotherapy in patients with unresectable stage III non-small cell lung cancer.
Description from Medscape.
Who is covering this
-
Benmelstobart Extends PFS After Chemoradiotherapy in NSCLC
Researchers evaluate benmelstobart, with or without anlotinib, for use as consolidation therapy after chemoradiotherapy in patients with unresectable stage III non-small cell lung cancer.
Comments
Comments need JavaScript.